Skip to main content
Clinical Trials/EUCTR2018-002471-18-GB
EUCTR2018-002471-18-GB
Active, not recruiting
Phase 1

The clinical effectiveness and cost effectiveness of clozapine for inpatients with borderline personality disorder: randomised controlled trial - CALMED

Imperial College London0 sites222 target enrollmentJune 19, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Imperial College London
Enrollment
222
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 19, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Aged 18 years or over
  • 2\) Currently an inpatient on a mental health unit
  • 3\) Meeting DSM\-IV diagnostic criteria for borderline personality disorder
  • 4\) Failure to make an adequate clinical response to taking antipsychotic medication other than clozapine for at least three months
  • 5\) Have a satisfactory pre\-treatment full blood count (white blood cell count \>\=3\.5 and absolute neutrophil count \>\=2\.0\)
  • 6\) Have had their weight and blood glucose recoded in their clinical records
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 219

Exclusion Criteria

  • We will exclude those who:
  • 1\) have a current clinical diagnosis of schizophrenia, or bipolar I disorder
  • 2\) prescribed clozapine within the last two weeks
  • 3\) are known to be pregnant, trying to conceive, breastfeeding, or a woman of childbearing potential and is not using a highly
  • effective birth control.
  • 4\) are due to be discharged from the unit within the following two weeks
  • 5\) are unable to speak sufficient English to complete the baseline assessment
  • 6\) are unwilling or unable to provide written informed consent to take part in the study
  • 7\) are unable to undergo regular blood tests
  • 8\) have a contraindication to clozapine or other listed condition, namely:

Outcomes

Primary Outcomes

Not specified

Similar Trials